Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
about
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasisProfile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisManaging Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabA patient-centred approach to biological treatment decision making for psoriasis: an expert consensusPsoriasis and comorbid diseases: Implications for management.Psoriasis and comorbid diseases: Epidemiology.Under-Treatment of Patients with Moderate to Severe Psoriasis in the United States: Analysis of Medication Usage with Health Plan DataThe Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.Update on biologic safety for patients with psoriasis during pregnancy.Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightPatient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database.Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment.An open label pilot study of supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis.Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis.Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic UseTreatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.Worldwide utilization of topical remedies in treatment of psoriasis: a systematic review.Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritisUS Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors.Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis surveyAn evolution in switching therapy for psoriasis patients who fail to meet treatment goals.Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience.Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic diseaseEffect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.Safety and tolerability of tumor necrosis factor-α inhibitors in psoriasis: a narrative review.Patterns of Systemic Treatment for Psoriatic Arthritis in the United States: 2004-2015.Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients.The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature.Medical adherence to topical corticosteroid preparations prescribed for psoriasis: A systematic review.Current challenges and emerging drug delivery strategies for the treatment of psoriasis.Experience and challenges for biologic use in the treatment of moderate-to-severe psoriasis in Africa and the Middle East region.Tofacitinib for the treatment of psoriasis.
P2860
Q26745789-5AFA6411-A3B6-4D8E-964A-43A9FB2F0EEFQ26765028-6A4C6957-10DC-481D-8196-C0EA5E1DBC01Q26771785-EBFDC58B-8717-412A-99CF-29840830AB3CQ28069819-27FB65E8-A0AE-45BA-BC34-18CBE235CBCCQ28082166-5A89E085-498D-4B4B-81C9-F8C6A4A961A4Q30235888-B01CD88D-3D17-423B-A1C6-A2A02575EF07Q30235889-70B60580-7E52-46EA-82D4-6E2F1B274153Q31146263-2E64E96D-98CE-407A-AC30-A084C3D449C3Q33572834-55BC8858-BD31-41AC-82BC-C22C571F61A8Q33641685-D0259484-0EDC-42B4-A745-3B6DB878755DQ33729774-E73DF590-C8A0-4618-9F5E-9A311513B19BQ34196035-B87A94D4-AC63-498E-91DC-32A4E26A9ECBQ34981499-259CB26A-4888-436A-A6E1-12FF1D685393Q35606402-3F4ADBFD-97EE-4B89-808A-E36D2F48380FQ35658540-B76ECA00-FA6D-4934-B8EB-21F82F28A569Q35761659-DBBB555A-4AE4-478C-B8A9-12FDE4CFC329Q35766545-3BD03546-86A7-4CBD-A3C2-1FAC44918B91Q35996755-F043ADD4-7052-476C-8C86-0E1C70D035BAQ36157003-E50D2D3B-56BC-48FE-96A2-462AA03595AAQ36175745-164059A0-BBDE-4820-9F4C-158D8ED480A8Q36264972-7961EEA4-CF35-4689-840D-E1093279E3EDQ36521222-CF422731-C4E5-4378-A031-23C130DD0AC2Q36628064-2B5CE849-FA18-4D69-B0AA-7C3B5CDB7898Q36996299-4CE138C2-DAE2-42BA-B0E0-79FE3C4FE58AQ37036355-30A5DAED-59E0-45B3-9B99-E2448435CD37Q37208460-A72BA0EA-9100-4C61-B6B1-FEBD5CBA3EF2Q37268881-B5F1E780-C89C-46EC-91C0-53938D25D9B5Q37295966-29E07FE9-5E45-49D8-995C-8080BA0A2C8FQ37308871-FFE929E3-BB3A-415E-81E4-EED593CF0B26Q37412781-D2697E80-83F0-493E-BA8B-25A8B7AF4BA8Q37505449-80E720E2-E016-404B-A333-8502CB46E452Q37631750-A8BF0A11-5523-4BCC-869C-D7D4DEAB75FAQ38166663-992ABC8A-8697-47CF-81A5-CB98D7589263Q38399089-1011BDA4-6114-4974-BFDB-C070A02786A3Q38672570-FB6F2E1F-AAF2-4AB3-AC9D-23050AF45A3CQ38681514-6E4C8EE3-92BE-480F-8CDB-6B889A2EBFE6Q38827236-4EF081F7-5606-48EC-82FC-C4389FBED7AEQ38831055-2B7AAB3E-0F35-4008-826C-4FC8C8A7DD96Q38838470-B2BCC40D-EB04-4A96-A2F3-282A823F2D72Q38856883-F53AFEF8-1B37-4D5C-AC7E-0B737BF3601F
P2860
Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Undertreatment, treatment tren ...... Foundation surveys, 2003-2011.
@en
Undertreatment, treatment tren ...... Foundation surveys, 2003-2011.
@nl
type
label
Undertreatment, treatment tren ...... Foundation surveys, 2003-2011.
@en
Undertreatment, treatment tren ...... Foundation surveys, 2003-2011.
@nl
prefLabel
Undertreatment, treatment tren ...... Foundation surveys, 2003-2011.
@en
Undertreatment, treatment tren ...... Foundation surveys, 2003-2011.
@nl
P2093
P1433
P1476
Undertreatment, treatment tren ...... Foundation surveys, 2003-2011.
@en
P2093
Andrew D Robertson
April W Armstrong
Clayton Schupp
Mark G Lebwohl
P304
P356
10.1001/JAMADERMATOL.2013.5264
P407
P577
2013-10-01T00:00:00Z